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1. Introduction 
Human tissue factor pathway inhibitor-2 (TFPI-2) is an extracellular matrix-associated 
Kunitz-type serine proteinase inhibitor that inhibits the plasmin- and trypsin-mediated 
activation of matrix metalloproteinases and inhibits tumor progression, invasion and 
metastasis. Previous studies have shown that TFPI-2 is downregulated in the progression of 
various tumors. Here we aim to investigate the expression and function of TFPI-2 in 
hepatocellular carcinoma (HCC). In situ hybridization and immunohistochemical analyses 
revealed that the expression of TFPI-2 in hepatocarcinoma tissues was markedly lower than 
that in tumor-adjacent normal hepatic tissues. Restored expression of TFPI-2 in HepG2 cells 
inhibits cell proliferation and invasion. Taken together, our results suggest that TFPI-2 plays 
tumor-suppression function and its inactivation may contribute to HCC. 
2. TFPI-2 expression in normal hepatic and hepatocarcinoma tissues  
2.1 Tissue specimens 
Human hepatocarcinoma tissues and tumor-adjacent normal hepatic tissues were obtained 
from HCC patients admitted to Shenzhen People's Hospital. They were stored frozen at -
75˚C until use.  
2.2 In situ hybridization 
Tumor specimens were fixed in formalin overnight and embedded in paraffin using 
standard procedures. Series sections (4um) were deparaffinized with xylene, rehydrated in a 
graded series of ethanol, and washed in PBS. Human TFPI-2 mRNA was detected using the 
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In Situ Hybridization Detection Kit (Boster, Wuhan, China) according to the manufacturer's 
instructions. Briefly, the sections were hybridized in prehybridization buffer supplemented 
with 0.1 ug/ml  digoxigenin-labeled, 1.2-kb antisenese TFPI-2 probe overnight at 37˚C and 
incubated with biotinylated mouse antidigoxigenin antibody (1:1000 dilution), then 
incubated with biotinylated peroxidase. Staining was developed with DAB. Slides were 
counterstained with hematoxylin, dehydrated, and mounted. The number of cells stained 
brown (indicating the presense of TFPI-2 mRNA) were assessed by light microscopy. The 
hybridization probe replaced with PBS was used as a negative control. Mature placenta 
tissue, known to express large amounts of TFPI-2, was used as a positive control. 
2.3 Immunohistochemistry 
Tissue sections were prepared in the same manner as above. Then the expression of TFPI-2 
was determined by incubation with a mouse polyclonal antibody against human TFPI-2 (Santa 
Cruz, CA), horseradish peroxidase (HRP)-conjugated sheep anti-mouse lgG secondary 
antibodies (Chinagen, Shenzhen, China), and final detection using the non Biotin-labeled 
 
Fig. 1. TFPI-2 expression in normal hepatic and hepatocarcinoma tissues. Expression of (A) 
TFPI-2 mRNA in hepatocarcinoma tissue and (B) tumor-adjacent normal hepatic tissue was 
examined by in situ hybridization with a digoxigenin-labeled TFPI-2 probe. Expression of (C) 
TFPI-2 protein in hepatocarcinoma tissue and (D) tumor-adjacent normal hepatic tissue was 
examined by immunohistochemical analyses with TFPI-2 antibody. Magnification, x400. 
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Detection Kit (Zhongshan Goldbridge, Beijing, China) according to the manufacturer's 
instructions. Staining was developed with DAB, slides were counterstained  with 
hematoxylin, dehydrated, and mounted. The primary antibody replaced with PBS was used 
as a negative control.Mature placenta tissue, known to express large amounts of TFPI-2,was 
used as a positive control.   
In situ hybridization with TFPI-2 probe demonstrated that little or no TFPI-2 mRNA was 
detected in hepatocarcinoma tissue sections, while a high level of TFPI-2 mRNA was 
detected in tumor-adjacent normal hepatic tissue sections (Fig. 1A, B). The positive and 
negative controls confirmed the specifility of hybridization liquid replaced with PBS used as 
a negative control confirmed the absence of a specific hybridization signal (data not shown). 
Further immunohistochemical analysis confirmed that TFPI-2 protein was stained strongly 
positive in normal hepatic tissues but was weakly stained in hepatocarcinoma tissues (Fig. 
1C, D). The TFPI-2 immunostaining scores for normal hepatic tissues and hepatocarcinoma 
tissues were 46.60±1.80 and 22.54±1.22, respectively (P<0.05). Taken together, these data 
indicate that the expression of TFPI-2 was markedly reduced in hepatocarcinoma tissues. 
3. TFPI-2 plasmid expression vector construct 
3.1 TFPI-2 gene sequencing 
The RNA from hepatic tissue of human fetor (Shenzhen People's Hospital) was isolated and 
full length TFPI-2 cDNA was amplified with RT-PCR kit (TaKaRa). The cloned gene was 
inserted into plasmid pcDNA2.1 (Chinagen, Shenzhen, China), and sequenced from forward 
and reverse direction at Shanghai Biotechnology (China), then it was inserted into 
eukaryotic expression vetor pcDNA3.1, a gift from Dr Tiyuan Li (Central Laboratory, 
Shenzhen People's Hospital) verified by enzyme digestion and sequencing. 
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Fig. 2. Homology analysis of TFPI-2 gene 
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3.2 Plasmid construct 
A 0.7-kb fragment encoding TFPI-2 cDNA was amplified from normal liver tissue with the 
primers 5'-GCTTTCTCGGACGCCTTGC-3' and 5'-GAATACGACCCCAAGAAATGAGTGA-
3'. PCR product was purified and cloned into the BamHΙ and XhoΙ sites of the pCDNA3.1 
expressing vector. The DNA sequence of the recombinant plasmid was confirmed via DNA 
sequencing. 
The Chinese TFPI-2 gene is 1222bp. Sequencing results showed that the cloned Chinese 
TFPI-2 gene has three bases different (258, 585 and 884 bp) with that registered in Genbank 
(Fig. 2). Our sequencing results has been transmitted and accepted by Genbank, accession 
number is TFPI AY691946. TFPI-2 gene was inserted to eukaryotic expression vetor 
pcDNA3.1 successfully. The result of nucleotide sequencing confirmed that the recombinant 
vector pcDNA3.1-TFPI-2 was constructed accurately. 
4. Construct HepG2-TFPI-2 stable cell line 
4.1 Cell culture and transfection  
To explore the functional role of TFPI-2 in HCC, we employed HepG2 cells as a model. 
Based on RT-PCR, we found that the expression of TFPI-2 mRNA in HepG2 cells was 
undetected (data not shown), therefore we introduced TFPI-2 into HepG2 cells by 
establishing HepG2-TFPI-2 stable cell line. 
Human hepatoma HepG2 cells were obtained from Cancer Institute, Chinese Academy of 
Medical Sciences, and cultured in 6% CO2 to 94% air and 96% humidity at 37˚C in DMEM 
supplemented with 10% bovine calf serum (Hyclone, Logan, UT), 1.0% glutamine, 100 
ug/ml strepotomycin, 100 ug/ml penicillin. The recombinant constructs or pCDNA3.1 
vector was transfected into HepG2 cells using Lipofectamine 2000 transfection reagent 
(Invitrogen) according to the manufacturer's instructions. Selection of transfected cells 
with 0.8 mg/ml G418 sulfate (Invitrogen) was initiated 48 h after transfection. After a 4-
week selection, stable transfectants were expanded  and used for the study. The HepG2 
cells were divided into three groups: HepG2 parental cells (HepG2-P), HepG2 cells 
transfected by pCDNA3.1 vector (HepG2-V) and HepG2 cells transfected  by TFPI-2 
construct (HepG2-TFPI-2). 
4.2 RT-PCR 
Total RNA was isolated from HepG2 cells using TRIZOL reagent (Invitrogen) following a 
standard protocol. Using the 2-step RT-PCR kit (TaKaRa), cDNA was synthesized with RNA 
as the template. PCR amplification of human TFPI-2 and ß-actin was performed with Taq 
Master Mix (Promega, Madison, WI, USA) with synthesized cDNA. The primer were 
synthesized by Shanghai Biotechnology (China) as follows: TFPI-2 5'- 
ATAGGATCCACATGGACCCGCTCGC-3' 
and 5'-GGCCTCGAGAAATTGCTTCTTCCGAATTTCC-3', amplicion 700 bp. ß-actin  
5'-CTGGCACCACACCTTCTACAATG-3' and 5'-AATGTCACGCACGATTTCCCGC-3'. The 
PCR condition were: denaturing at 95˚C for 30 sec, annealing at 52˚C for 30 sec, and 
extension at 72˚C for 40 sec for 32 cycles. After electrophoresis of PCR products, the data 
were analyzed by Image Master Tatal Laboratory ID software. The level of TFPI-2 mRNA 
was calculated by the ratio of density of TFPI-2 to ß-actin. 
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4.3 Western blot 
HepG2-P HepG2-TFPI-2 and HepG2-V cells were grown to 80-90% confluence in six-well 
plates, after which the medium was replaced with serum-free medium and incubated for 24 
h. Then the cultures were washed several times with PBS and the ECM was prepared as 
described by Rao et al  (15). The ECM protein were supplemented with PMSF (1 mmol/L) to 
inhibit the proteases. The  samples was mixed with equal volume of 2×SDS sample buffer 
and boiled for 5 min. Equal amounts of protein were resolved on 12% sodium dodecyl 
sulfate (SDS)-polyacrylamid gels, and then transfected onto polyvinylidene difluoride 
(PVDF) membrane (Millopore). After blocking with 5% non-fat milk, the membranes were 
incubated, first with primary antibody at 4˚C overnight and then with horseradish 
peroxidase (HRP)-conjugated sheep anti-mouse lgG secondary antibody. After washing, the 
blots were developed with a super-Enhanced Chemiluminescence Detection Kit (Applygen 
Technologies, Beijing, China). 
By Western blot we found that a high level of TFPI-2 protein was detected in conditioned 
media of HepG2-TFPI-2 cells but not in that of HepG2-V or the HepG2-P cells (Fig. 3). These 
results proved that we successfully introduced TFPI-2 into HepG2 cells. 
 
Fig. 3. Secretion of TFPI-2 in the conditioned media from HepG2-TFPI-2 cells. The 
conditioned media were collected from lanes 1, HepG2-P cells; 2, HepG2-TFPI-2 cells and 3, 
HepG2-V cells, and analyzed by Western blotting. 
5. Cell proliferation assay 
Cell proliferation was evaluated by MTT assay (sigma) according to a procedure described 
previously (16). In brief, every 24 h, for a total of 7 days, the cells from the three groups were 
harvested and 200 ul of cell suspension was added to each well in 96-well plates. A one-
tenth volume of MTT solution (5 mg MTT/ml PBS) was added to each well and incubated 
for 2-4 h at 37˚C until a purple precipitate was visible. The medium was then carefully 
removed, and precipitates were dissolved in 150 ul DMSO. Growth rate was plotted as the 
percentage of viable cells in HepG2-P control (a value arbitrarily set at 100%). Each 
experiment was repeated at least three times with each treatment given in duplicate or 
triplicate. Data were presented as an average of the results from individual experiments. 
We examined the effect of TFPI-2 expression on the proliferation  of HepG2 cells. The viability 
of cells was determined by MTT assay for 7 days and cell proliferation was obviously inhibited 
on the fourth day in HepG2-TFPI-2 cells but not in the other two groups of cells (Fig. 4). These 
results suggested that TFPI-2 could suppress the growth of hepatocarcinoma cells.  
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Fig. 4. The growth curve of different groups of HepG2 cells (HepG2-P, HepG2-V and HepG2-
TFPI-2). 
6. In vitro cell migration and invasion assay 
Invasion and migration of the hepatocarcinoma cells in vitro was measured by the invasion 
of cells through Matrigel-coated or -uncoated transwell inserts according to a procedure 
described previously (17). Briefly, transwell inserts (Corning) with 8-um pore size were 
coated (for invasion assay) or uncoated (for migration assay) with 50 ug of Matrigel matrix 
(BD Biosciences). Cells suspended in serum-free DMEM medium were seeded into upper 
chambers (100 ul/well) at a density of 1×10^6 cells/ml (for migration assay) or 3×10^5 
cells/ml (for invasion assay). The lower chambers were filled with DMEM supplemented 
with 10% FBS. After 24 h of incubation,  cells attached to the upper side of the filter were 
removed, and the filters were fixed and stained with hematoxylin and eosin. At this point, 
there was no difference in the total number of cells (proliferation rate) among the groups in the 
serum-free medium. The number of cells that had migrated to the undersurface of the 
membrane was counted in five randomly-selected microscopic fields in each sample. 
 
Groups Membranes in matrigel invasion assay
1 2 3 4 5 x ±s 
HepG2-TFPI-2 45 53 39 48 41 49.3 ± 5.9 * 
HepG2-V 91 93 80 79 88 86.2 ± 6.4 
HepG2-P 90 86 93 81 89 87.8 ± 4.5 
 
Groups Membranes in migration assay
1 2 3 4 5 x ±s 
HepG2-TFPI-2 142 132 139 152 137 140.4 ± 7.4 
HepG2-V 134 148 160 140 147 145.8 ± 9.8 
HepG2-P 150 166 159 142 147 152.8 ± 9.6 
* p< 0.05 vs HepG2-V or HepG2-P 
Table 1. In vitro invasion of different groups of HepG2 cells 
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We went further to examine the effect of TFPI-2 expression on the invasion of HepG2 cells. 
Based on invasion and migration assays, we counted the cells that passed through the 
membranes (Table 1). The results show that the number of cells passing through the 
membranes was significantly lower in the HepG2-TFPI-2 group than the other two groups ( 
P<0.05), indicating that TFPI-2 suppresses the invasive potential of hepatocarcinoma cells. 
While no significant difference in migration ability was observed in the three groups (Table 1). 
7. Statistical analysis 
All data were presented as mean±SD. Stastical analysis was performed with SPSS statistical 
software. The Student two-tailed t test was used to compare the difference between groups, 
p<0.05 was considered to be statistically significant. 
TFPI-2 is a serine proteinase inhibitor which is frequently downregulated in malignant 
tumors  (18). Previous studies have demonstrated that silencing of TFPI-2 by either histone 
deacetylation (19) or promoter hypermethylation contributes to its inactivation and tumor 
progression in several cancers including glioma (18), choricarcinoma (20), pancreatic 
carcinoma (17), lung carcinoma (21), breast cancer (22), melanoma (23) and hepatocarcinoma 
(24). In addition, the aberrant splicing form of TFPI-2 was detected during cancer 
progression (25), which represents an untranslated form providing another mechanism by 
which TFPI-2 is downregulated in tumor cells. 
In this study, we investigated the expression and function of TFPI-2 in HCC. We first applied the 
in situ hybridization and immunohistochemistry methods to evaluate the expression of TFPI-2 
mRNA and protein in hepatocarcinoma tissues and tumor-adjacent normal hepatic tissues. 
Consistent with previous studies, our results showed that TFPI-2 expression at both mRNA and 
protein levels was low in hepatocarcinoma tissues compared to adjacent normal hepatic tissues. 
These results indicated that a decreased expression of TFPI-2 is implicated in HCC. 
To find the mechanism by which TFPI-2 loss contributes to HCC, we employed HepG2 cells as 
a model. Our results demonstrate that reconstitution of TFPI-2 into HepG2 cells could inhibit 
the proliferation and invasion of HepG2 cells. Although the details for TFPI-2-mediated 
growth suppression are unknown, a previous study suggested that TFPI-2 induces apoptosis 
in glioma cells (26). Further studies are necessary to examine whether TFPI-2 promotes 
apoptosis of HepG2 cells. In agreement with previous reports that overexpression of TFPI-2 
reduced the invasion of cancer cell lines derived from melanoma (27), prostate cancer (28), 
choriocarcinoma (29), glioblastoma (30) or meningiomas (31), our results showed that 
restoration of TFPI-2 was associated with a twofold decrease in invasive ability of HepG2 cells. 
In fact, TFPI-2 is thought to play a pivotal role in the regulation of plasmin-mediated ECM 
proteolysis during tumor invasion and metastasis (14). TFPI-2 inhibits the release of plasmin- 
or trypsin-dependent activation of pro-matrix metalloproteinase (MMP)-1 and pro-MMP-3, 
which leads to diminished ECM degradation and decreased invasion of HT-1080 fibrosarcoma 
cell lines (32, 33). In addition, TFPI-2 can inhibit MMP-2 activation in HT-1080 cells (34) and 
inhibit MMP-1, MMP-13, MMP-2 and MMP-9 in experimental models (35). Thus we assume 
that TFPI-2 inhibits HCC invasion and metastasis through modulating the activity of MMPs. 
In summary, we reported that TFPI-2 expression is lost in HCC. The results of our in vitro 
studies confirm that restoration of TFPI-2 caused decreased proliferative and invasive 
behaviors of HepG2 cells. Taken together, these data suggest that inactivation of TFPI-2 may 
contribute to the malignant behavior in hepatocarcinoma. Additional in vivo studies will 
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help determine whether restoration of TFPI-2 in hepatocarcinoma cells may represent a 
novel therapeutic approach for HCC. 
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